Oncology Certified Nurse (OCN) Nursing Practice Test (Sample)

Study Guide

Everything you need from our exam experts!

Questions

1. What chromosomal abnormality is frequently observed in renal cell carcinoma?

A. Chromosome 17p

B. Chromosome 3p

C. Chromosome 10q

D. Chromosome 12q

2. In oncology nursing, why is communication with patients crucial?

A. To follow hospital protocols

B. To gather information for medical records

C. To ensure patients understand their treatment

D. To maintain the nurse's professional image

3. Which chromosome is most commonly abnormal in renal cell carcinoma?

A. Chromosome 5p

B. Chromosome 3p

C. Chromosome 20q

D. Chromosome 17

4. What laboratory finding indicates an unfavorable prognosis for a patient diagnosed with Hodgkin lymphoma?

A. Hemoglobin 11 g/dL

B. Involvement of two lymph nodes

C. Absolute lymphocyte count 400/mm3

D. Presence of A symptoms

5. Which of the following chemotherapeutic agents is used to treat malignant melanoma?

A. Doxorubicin

B. Lomustine

C. Cyclophosphamide

D. Gemcitabine

6. What nursing education is recommended for patients experiencing dumping syndrome?

A. High carbohydrate meals

B. Small, frequent meals

C. Increased fluid intake

D. Avoiding all fiber

7. Which diagnostic tests are typically used for esophageal cancer?

A. Chest X-ray and MRI

B. Esophagoscopy and biopsy

C. CT and PET scan

D. Ultrasound and blood tests

8. What is the most effective single-agent chemotherapy for bladder cancer?

A. Cisplatin

B. Carboplatin

C. Paclitaxel

D. Doxorubicin

9. What is a major toxicity associated with cisplatin?

A. Cardiotoxicity

B. Nephrotoxicity

C. Neurotoxicity

D. Myelosuppression

10. In lung cancer, which cell type is commonly associated with increased hormone levels?

A. Adenocarcinoma

B. Small cell lung cancer

C. Non-small cell lung cancer

D. Large cell carcinoma

Answers

1. B
2. C
3. B
4. C
5. B
6. B
7. B
8. A
9. B
10. B

Explanations

1. What chromosomal abnormality is frequently observed in renal cell carcinoma?

A. Chromosome 17p

B. Chromosome 3p

C. Chromosome 10q

D. Chromosome 12q

The frequent observation of chromosomal abnormalities in renal cell carcinoma highlights the significance of chromosome 3p, which is particularly known for its association with this type of cancer. The most common subtype of renal cell carcinoma is clear cell carcinoma, which is often linked to the loss of heterozygosity on chromosome 3p. This loss typically involves tumor suppressor genes, including the VHL (von Hippel-Lindau) gene, which plays a crucial role in cellular growth regulation and apoptosis. When there is a deletion or mutation in chromosome 3p, it can lead to uncontrolled cell proliferation and contribute to tumor development. This chromosomal region's abnormalities are well-documented in both familial and sporadic cases of renal cell carcinoma, making chromosome 3p a key focus in understanding the pathology of this cancer. In contrast, while other chromosomes may harbor abnormalities in different cancers or even within rarer subtypes of renal cell carcinoma, chromosome 3p has a strong and established connection to the pathogenesis of the more common forms of renal cell carcinoma, solidifying its importance in both research and clinical practice.

2. In oncology nursing, why is communication with patients crucial?

A. To follow hospital protocols

B. To gather information for medical records

C. To ensure patients understand their treatment

D. To maintain the nurse's professional image

Communication with patients is crucial in oncology nursing primarily because it ensures that patients understand their treatment. Effective communication involves not only delivering information about diagnosis, treatment options, and potential side effects but also checking for comprehension and addressing any concerns or questions the patient may have. Patients often experience anxiety and uncertainty regarding their cancer diagnosis and treatment. Clear communication can empower them to make informed decisions about their care, improving adherence to treatment plans and enhancing their overall experience during a challenging time. Moreover, understanding their treatment helps patients feel more in control and can lead to better outcomes, as they are more likely to report side effects or complications in a timely manner. In this context, while following hospital protocols and gathering information for medical records are important components of nursing practice, they are secondary to the foundational role that understanding plays in patient care in oncology. Maintaining a professional image is also significant, but it is ultimately aimed at promoting trust and engagement, which stems from effective communication with the patient about their treatment and care options.

3. Which chromosome is most commonly abnormal in renal cell carcinoma?

A. Chromosome 5p

B. Chromosome 3p

C. Chromosome 20q

D. Chromosome 17

Renal cell carcinoma (RCC) is often associated with specific genetic changes, and one of the most notable is the alteration of chromosome 3. In particular, losses of heterozygosity at the 3p position are frequently observed in RCC. This region of the chromosome harbors the VHL (von Hippel-Lindau) gene, which is a tumor suppressor gene that plays a crucial role in regulating cell growth and apoptosis. When this gene is mutated or deleted, it can lead to uncontrolled cell proliferation and the development of renal cell carcinoma. The association of chromosome 3p anomalies with renal cell carcinoma is significant in both the pathogenesis and the potential development of targeted therapeutic strategies. Understanding these genetic abnormalities assists healthcare providers in offering more informed prognostic information and treatment options for patients diagnosed with RCC. The presence of other abnormal chromosomes, while relevant to various cancers, does not have the same established correlation with RCC as chromosome 3p.

4. What laboratory finding indicates an unfavorable prognosis for a patient diagnosed with Hodgkin lymphoma?

A. Hemoglobin 11 g/dL

B. Involvement of two lymph nodes

C. Absolute lymphocyte count 400/mm3

D. Presence of A symptoms

An absolute lymphocyte count of 400/mm3 is recognized as an unfavorable prognostic indicator in patients diagnosed with Hodgkin lymphoma. A low absolute lymphocyte count at diagnosis has been associated with a poorer overall survival rate and less favorable response to treatment. Lymphocytes play a crucial role in the immune response, and a low count may suggest a compromised immune system or higher tumor burden, both of which can negatively impact patient outcomes. In contrast, hemoglobin levels, while important, do not universally correlate with prognosis in Hodgkin lymphoma. Although anemia can suggest a more advanced disease state, it is not as definitive a factor as lymphocyte count when evaluating prognosis. The involvement of two lymph nodes represents early stage involvement and is less significant in terms of prognostic value compared to the lymphocyte count. Lastly, the presence of "A symptoms" (such as fever, night sweats, and weight loss) are related to a patient's symptomatology and can be present in various stages of the disease, but they do not directly indicate a poor prognosis as the absolute lymphocyte count does.

5. Which of the following chemotherapeutic agents is used to treat malignant melanoma?

A. Doxorubicin

B. Lomustine

C. Cyclophosphamide

D. Gemcitabine

Lomustine is a nitrosourea chemotherapy agent that is effective in treating malignant melanoma, particularly in cases where the disease has metastasized. It works by interfering with the DNA synthesis of cancer cells, ultimately leading to cell death. This mechanism is significant as melanoma often presents challenges in treatment due to its ability to metastasize, so effective chemotherapy options are crucial for managing advanced stages of this cancer. Doxorubicin, while a powerful chemotherapy agent, is traditionally more effective against other cancers such as breast cancer and certain leukemias, making it less relevant for malignant melanoma specifically. Cyclophosphamide is commonly used in a variety of cancers but is not the first line of treatment for melanoma. Gemcitabine is primarily used for cancers of the pancreas and bladder, among others, and does not hold a strong role in melanoma management. Understanding the specificity of chemotherapeutic agents and their applications is essential for effective treatment planning in oncology.

6. What nursing education is recommended for patients experiencing dumping syndrome?

A. High carbohydrate meals

B. Small, frequent meals

C. Increased fluid intake

D. Avoiding all fiber

For patients experiencing dumping syndrome, the recommendation of small, frequent meals is crucial for managing symptoms effectively. Dumping syndrome occurs when food moves too quickly from the stomach to the small intestine, leading to symptoms such as nausea, cramping, and diarrhea. By encouraging small, frequent meals, patients can reduce the volume of food entering the digestive system at one time. This approach helps to slow down gastric emptying and provides the intestines with a better chance to absorb nutrients effectively, minimizing unpleasant symptoms. Additionally, smaller meals can help prevent rapid fluctuations in blood sugar levels that often accompany larger meal consumption. The focus on portion control and meal frequency allows for a more manageable digestion process and can improve the overall quality of life for those affected by dumping syndrome. Hence, this dietary modification is a key educational point for nurses to convey to patients dealing with this condition.

7. Which diagnostic tests are typically used for esophageal cancer?

A. Chest X-ray and MRI

B. Esophagoscopy and biopsy

C. CT and PET scan

D. Ultrasound and blood tests

Esophagogastroduodenoscopy (EGD), often referred to as esophagoscopy, is a key diagnostic tool used in the evaluation of esophageal cancer. During this procedure, a thin, flexible tube with a light and camera at the end is inserted through the mouth and into the esophagus, allowing for visualization of the esophageal lining. This direct view helps identify any abnormalities, such as tumors, ulcers, or inflammation. Biopsy is performed during esophagoscopy when a suspicious area is detected. Tissue samples are collected and sent to a pathology lab for examination under a microscope. The biopsy plays a critical role in confirming the diagnosis of esophageal cancer, determining the type of cancer, and assessing its grade. In contrast, chest X-rays can provide general information about potential metastatic spread but lack specificity for diagnosing esophageal cancer. MRI, while useful for some cancers, is not typically the first-line imaging modality for evaluating esophageal tumors. CT and PET scans are valuable in staging and assessing the extent of the disease but are not primary diagnostic tests. Similarly, ultrasound and blood tests may contribute to the overall assessment of a patient but do not directly diagnose esophageal cancer. Thus, esophagoscopy combined with biopsy stands out as the

8. What is the most effective single-agent chemotherapy for bladder cancer?

A. Cisplatin

B. Carboplatin

C. Paclitaxel

D. Doxorubicin

Cisplatin is recognized as the most effective single-agent chemotherapy for bladder cancer due to its strong antitumor activity, particularly in muscle-invasive and metastatic bladder cancer. Its effectiveness stems from its ability to form DNA cross-links, preventing DNA replication and transcription, which ultimately leads to cancer cell death. This mechanism makes cisplatin a cornerstone in the treatment of bladder cancer and, in many instances, a preferred option when a patient is eligible for cisplatin-based chemotherapy regimens. In comparison, while carboplatin can be used in cases where patients are not suitable for cisplatin due to toxicity or other contraindications, it is generally less effective than cisplatin in treating bladder cancer. Paclitaxel has applications in various cancers and can be utilized in the treatment of bladder cancer, especially in combination regimens, but it does not have the same level of effectiveness as a single agent compared to cisplatin. Doxorubicin, though a potent chemotherapeutic agent, has not demonstrated the same success in bladder cancer as cisplatin, and it is less commonly used as first-line treatment. Thus, cisplatin stands out as the most effective choice among these options for bladder cancer treatment.

9. What is a major toxicity associated with cisplatin?

A. Cardiotoxicity

B. Nephrotoxicity

C. Neurotoxicity

D. Myelosuppression

Cisplatin is a widely used platinum-based chemotherapy agent that is particularly effective against various solid tumors. A major concern when administering cisplatin is its association with nephrotoxicity, which is characterized by damage to the kidneys. This toxicity arises because cisplatin is primarily excreted by the kidneys, leading to the accumulation of the drug within renal tissues. The resulting oxidative stress and inflammation contribute to acute kidney injury, which may manifest as elevated serum creatinine levels and electrolyte imbalances. Preventative strategies, such as hydration and the use of diuretics, can mitigate the risk of nephrotoxicity when administering cisplatin. Ongoing monitoring of renal function is essential in patients receiving this drug to ensure timely intervention if nephrotoxic effects occur. Understanding this significant adverse effect is crucial for oncology nurses, as they play a critical role in patient education and management during chemotherapy.

10. In lung cancer, which cell type is commonly associated with increased hormone levels?

A. Adenocarcinoma

B. Small cell lung cancer

C. Non-small cell lung cancer

D. Large cell carcinoma

Small cell lung cancer (SCLC) is known for its association with paraneoplastic syndromes, which can lead to increased hormone levels in the body. One of the most notable characteristics of SCLC is its ability to produce ectopic hormones, particularly antidiuretic hormone (ADH) and adrenocorticotropic hormone (ACTH). These hormones can disrupt normal hormonal balance and create a series of physiological changes. The presence of these hormones contributes to the distinct clinical manifestations observed in patients with SCLC, such as hyponatremia due to excess ADH or Cushing syndrome due to excess ACTH production. The capacity of small cell lung cancer to generate these hormones is a key feature that distinguishes it from other types of lung cancer, which tend to have a different clinical presentation and do not typically lead to increased levels of hormones through ectopic secretion. In contrast, adenocarcinoma, non-small cell lung cancer, and large cell carcinoma do not have the same propensity for hormone secretion as small cell lung cancer, making their hormonal profiles less dynamic in relation to paraneoplastic phenomena.